NuCana (NCNA) Income towards Parent Company (2017 - 2025)
NuCana (NCNA) reported Income towards Parent Company of -$3.7 million for Q4 2025, down 339.46% on a YoY basis from $1.5 million in Q4 2024, and down 871.39% sequentially from -$379170.8 in Q3 2025.
NuCana (NCNA) Income towards Parent Company (2017 - 2025) Analysis & Trends
NuCana (NCNA) has 9 years of Income towards Parent Company data on file, last reported at -$3.7 million in Q4 2025.
- For the quarter ending Q4 2025, Income towards Parent Company fell 339.46% year-over-year to -$3.7 million; the trailing twelve-month figure through Dec 2025 stood at -$39.3 million (down 62.57% YoY), and the FY2025 full-year result was -$41.8 million, down 72.06% from the prior year.
- Income towards Parent Company slipped to -$3.7 million in Q4 2025, from -$379170.8 in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $12.7 million in Q2 2021 to a low of -$32.2 million in Q2 2025.
- A 5-year average of -$7.9 million and a median of -$8.6 million in 2023 frame the typical range for Income towards Parent Company.
- Peak annual rise in Income towards Parent Company reached 268.77% in 2021, while the deepest fall reached 364.75% in 2021.
- Tracing NCNA's Income towards Parent Company over 5 years: stood at -$18.4 million in 2021, then rose by 3.07% to -$17.8 million in 2022, then surged by 46.71% to -$9.5 million in 2023, then jumped by 91.18% to -$838126.7 in 2024, then slumped by 339.46% to -$3.7 million in 2025.
- Business Quant data shows NCNA's Income towards Parent Company at -$3.7 million in Q4 2025, -$379170.8 in Q3 2025, and -$32.2 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | NuCana | 14.38 Bn | 14.34 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.68 Mn |
| Sep 30, 2025 | -379,170.76 |
| Jun 30, 2025 | -32.17 Mn |
| Mar 31, 2025 | -3.11 Mn |
| Dec 31, 2024 | -838,126.70 |
| Sep 30, 2024 | -5.86 Mn |
| Jun 30, 2024 | -8.83 Mn |
| Mar 31, 2024 | -8.67 Mn |
| Dec 31, 2023 | -9.50 Mn |
| Sep 30, 2023 | -8.48 Mn |
| Jun 30, 2023 | -6.77 Mn |
| Mar 31, 2023 | -9.56 Mn |
| Dec 31, 2022 | -17.83 Mn |
| Sep 30, 2022 | -5.34 Mn |
| Jun 30, 2022 | 4.90 Mn |
| Mar 31, 2022 | -11.28 Mn |
| Dec 31, 2021 | -18.39 Mn |
| Sep 30, 2021 | -11.09 Mn |
| Jun 30, 2021 | 12.70 Mn |
| Mar 31, 2021 | -13.46 Mn |